Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading on Wednesday. Stock investors bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical volume of 165 put options.
Xenon Pharmaceuticals Trading Down 1.3%
Shares of NASDAQ:XENE opened at $31.76 on Thursday. The stock has a 50 day moving average of $32.96 and a 200 day moving average of $35.82. The company has a market cap of $2.44 billion, a PE ratio of -9.83 and a beta of 1.09. Xenon Pharmaceuticals has a 12-month low of $26.74 and a 12-month high of $46.00.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same quarter last year, the firm posted ($0.62) earnings per share. Equities research analysts predict that Xenon Pharmaceuticals will post -3.1 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages recently commented on XENE. Chardan Capital reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Monday, May 5th. HC Wainwright reaffirmed a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Evercore ISI began coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price objective for the company. Finally, Royal Bank Of Canada cut their price objective on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $54.82.
Get Our Latest Stock Analysis on XENE
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Assetmark Inc. lifted its holdings in Xenon Pharmaceuticals by 9.7% in the 4th quarter. Assetmark Inc. now owns 21,585 shares of the biopharmaceutical company's stock worth $846,000 after purchasing an additional 1,915 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Xenon Pharmaceuticals in the 4th quarter worth approximately $797,000. Candriam S.C.A. lifted its holdings in Xenon Pharmaceuticals by 6.1% in the 4th quarter. Candriam S.C.A. now owns 492,181 shares of the biopharmaceutical company's stock worth $19,293,000 after purchasing an additional 28,320 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Xenon Pharmaceuticals by 17.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,274 shares of the biopharmaceutical company's stock worth $756,000 after purchasing an additional 2,866 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Xenon Pharmaceuticals by 1.0% in the 4th quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company's stock worth $4,963,000 after purchasing an additional 1,300 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.
About Xenon Pharmaceuticals
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
